Press Release
October 2, 2023

Goodwin Expands Life Sciences Practice with Capital Markets Partner Adam Johnson in New York

Global law firm Goodwin today announced that Adam Johnson joined the firm’s Life Sciences and Capital Markets practices as a partner, resident in the New York office.

“Adam’s broad-based capital markets and public company expertise, across debt, equity, issuer and underwriter sides, is a terrific addition to our market-leading offering for life sciences companies,” said Edwin O’Connor, co-chair of Goodwin’s Capital Markets practice. “We are delighted to welcome him to Goodwin as we continue to support our clients who are pursuing opportunities in the public markets.”

Adam represents many leading financial institutions and companies at all levels of corporate structure. He advises clients on corporate governance issues, SEC reporting, investments and accessing capital through initial public offerings, equity financings, secured and unsecured high-yield debt, private capital transactions, and other corporate, finance and securities matters. Adam advises clients on a variety of transactions within many fields, including life sciences, healthcare, technology, entertainment, fintech, and retail and consumer products.

Goodwin’s Capital Markets practice is routinely recognized for excellence around the world by Chambers, The Legal 500, and IFLR1000. Bloomberg's H1 2023 capital markets league tables highly rank Goodwin for its ability to advise clients on US equity linked capital markets transactions, as well as for US equity offerings on behalf of issuers, and global equity, equity linked, and rights transactions on behalf of issuers.

The Life Sciences practice works with companies throughout the corporate lifecycle – from startup and commercial-stage to maturity – as well as investors, banks, and others in the life sciences ecosystem.